Evidence map›Paper›PMID 30709501›Full record

ReviewClinics in laboratory medicine2019

MicroRNAs and Transplantation.

Zahraa Khan, Manikkam Suthanthiran, Thangamani Muthukumar

Abstract readReview
In one paragraph

Review in Clinics in laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. microRNA as an Important Mediator in the Regulation of MaleInternational journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. MicroRNAs in kidney injury and disease.Nature reviews. Nephrology · 2022
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zahraa KhanDivision of Nephrology and Hypertension, Department of Medicine, New York-Presbyterian-Weill Cornell Medicine, 525 East 68th Street, Box 3, New York, NY 10065, USA; Division of Nephrology and Hypertension, Department of Transplantation Medicine, New York-Presbyterian-Weill Cornell Medicine, 525 East 68th Street, Box 3, New York, NY 10065, USA.
Manikkam SuthanthiranDivision of Nephrology and Hypertension, Department of Medicine, New York-Presbyterian-Weill Cornell Medicine, 525 East 68th Street, Box 3, New York, NY 10065, USA; Division of Nephrology and Hypertension, Department of Transplantation Medicine, New York-Presbyterian-Weill Cornell Medicine, 525 East 68th Street, Box 3, New York, NY 10065, USA.
Thangamani MuthukumarDivision of Nephrology and Hypertension, Department of Medicine, New York-Presbyterian-Weill Cornell Medicine, 525 East 68th Street, Box 3, New York, NY 10065, USA; Division of Nephrology and Hypertension, Department of Transplantation Medicine, New York-Presbyterian-Weill Cornell Medicine, 525 East 68th Street, Box 3, New York, NY 10065, USA. Electronic address: mut9002@med.cornell.edu.

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
Biomolecular Markers for Safe Minimization of ImmunosuppressionR37AI051652 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SUTHANTHIRAN, MANIKKAM · 2009 to 2021
$4.7M
Biomolecular Markers of Renal Allograft StatusK08DK087824 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI MUTHUKUMAR, THANGAMANI · 2011 to 2015
$658k
Noninvasive Biomarkers of Microcirculatory Injury in the Human Kidney AllograftR03DK105270 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI MUTHUKUMAR, THANGAMANI · 2016 to 2017
$170k
NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384NIAID NIH HHS R37 AI051652NIDDK NIH HHS K08 DK087824NIDDK NIH HHS R03 DK105270
6 · The paper itself

Abstract

miRNAs, ∼20 to 22 nucleotide single-stranded RNA species that play a pivotal role in the regulation of protein-coding genes, are emerging as robust biomarkers for assessing allograft status. Herein, the authors briefly review the biogenesis and function of the miRNAs and provide an overview of the tools to quantify miRNAs in tissues and body fluids. They then review their studies of discovery and validation of alterations in miRNA expression within kidney allografts with or without acute rejection, as well as with or without fibrosis, and summarize published data on miRNA expression patterns in kidney transplant recipients.

Indexed as

Kidney TransplantationCluster AnalysisGraft RejectionMicroRNAsSequence Analysis, RNAMicroRNAsBiomarkersKidney transplantationmiRNARejection

Identifiers

PMID30709501
PMCPMC6369703

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.